BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 25381132)

  • 1. Pharmacological targeting of β-catenin in normal karyotype acute myeloid leukemia blasts.
    Griffiths EA; Golding MC; Srivastava P; Povinelli BJ; James SR; Ford LA; Wetzler M; Wang ES; Nemeth MJ
    Haematologica; 2015 Feb; 100(2):e49-52. PubMed ID: 25381132
    [No Abstract]   [Full Text] [Related]  

  • 2. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
    Alachkar H; Santhanam R; Harb JG; Lucas DM; Oaks JJ; Hickey CJ; Pan L; Kinghorn AD; Caligiuri MA; Perrotti D; Byrd JC; Garzon R; Grever MR; Marcucci G
    J Hematol Oncol; 2013 Mar; 6():21. PubMed ID: 23497456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.
    Sanjiv K; Calderón-Montaño JM; Pham TM; Erkers T; Tsuber V; Almlöf I; Höglund A; Heshmati Y; Seashore-Ludlow B; Nagesh Danda A; Gad H; Wiita E; Göktürk C; Rasti A; Friedrich S; Centio A; Estruch M; Våtsveen TK; Struyf N; Visnes T; Scobie M; Koolmeister T; Henriksson M; Wallner O; Sandvall T; Lehmann S; Theilgaard-Mönch K; Garnett MJ; Östling P; Walfridsson J; Helleday T; Warpman Berglund U
    Cancer Res; 2021 Nov; 81(22):5733-5744. PubMed ID: 34593524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cup-like acute myeloid leukemia: new disease or artificial phenomenon?
    Kroschinsky FP; Schäkel U; Fischer R; Mohr B; Oelschlaegel U; Repp R; Schaich M; Soucek S; Baretton G; Ehninger G; Thiede C;
    Haematologica; 2008 Feb; 93(2):283-6. PubMed ID: 18223289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-aminoimidazole-4-carboxamide ribonucleoside induces differentiation in a subset of primary acute myeloid leukemia blasts.
    Dembitz V; Lalic H; Kodvanj I; Tomic B; Batinic J; Dubravcic K; Batinic D; Bedalov A; Visnjic D
    BMC Cancer; 2020 Nov; 20(1):1090. PubMed ID: 33176741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.
    Reis B; Jukofsky L; Chen G; Martinelli G; Zhong H; So WV; Dickinson MJ; Drummond M; Assouline S; Hashemyan M; Theron M; Blotner S; Lee JH; Kasner M; Yoon SS; Rueger R; Seiter K; Middleton SA; Kelly KR; Vey N; Yee K; Nichols G; Chen LC; Pierceall WE
    Haematologica; 2016 May; 101(5):e185-8. PubMed ID: 26869629
    [No Abstract]   [Full Text] [Related]  

  • 7. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
    Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-induction therapy in adult patients with acute myeloid leukemia with ≤20 % blasts: A retrospective cohort study.
    Kannan KK; Vellanki P; Isom S; Tawfik B; Winter A; Klepin HD; Ellis LR; Bhave RR; Howard D; Manuel M; Dralle S; Lyerly S; Powell BL; Pardee TS
    Leuk Res; 2021 Dec; 111():106731. PubMed ID: 34695644
    [No Abstract]   [Full Text] [Related]  

  • 9. Cell signaling in putative leukemic stem cells and blast population in acute myeloid leukemia.
    Garg S; Shanmukhaiah C; Ghosh K; Madkaikar M
    Leuk Lymphoma; 2016 Sep; 57(9):2195-8. PubMed ID: 26700494
    [No Abstract]   [Full Text] [Related]  

  • 10. PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene.
    Guo Z; Wang A; Zhang W; Levit M; Gao Q; Barberis C; Tabart M; Zhang J; Hoffmann D; Wiederschain D; Rocnik J; Sun F; Murtie J; Lengauer C; Gross S; Zhang B; Cheng H; Patel V; Schio L; Adrian F; Dorsch M; Garcia-Echeverria C; Huang SM
    Blood; 2014 Sep; 124(11):1777-89. PubMed ID: 25006129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of the MNK-eIF4E axis in blast crisis chronic myeloid leukemia inhibits leukemia stem cell function.
    Lim S; Saw TY; Zhang M; Janes MR; Nacro K; Hill J; Lim AQ; Chang CT; Fruman DA; Rizzieri DA; Tan SY; Fan H; Chuah CT; Ong ST
    Proc Natl Acad Sci U S A; 2013 Jun; 110(25):E2298-307. PubMed ID: 23737503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
    Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
    Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Podocalyxin is expressed in normal and leukemic monocytes.
    Riccioni R; Calzolari A; Biffoni M; Senese M; Riti V; Petrucci E; Pasquini L; Cedrone M; Lo-Coco F; Diverio D; Foà R; Peschle C; Testa U
    Blood Cells Mol Dis; 2006; 37(3):218-25. PubMed ID: 17059890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of CD200 on AML blasts directly suppresses memory T-cell function.
    Coles SJ; Hills RK; Wang EC; Burnett AK; Man S; Darley RL; Tonks A
    Leukemia; 2012 Sep; 26(9):2148-51. PubMed ID: 22430635
    [No Abstract]   [Full Text] [Related]  

  • 15. Erythrophagocytosis by blasts in acute myeloid leukaemia harbouring the BCR-ABL1 fusion gene.
    Murayama H; Matsushita H; Obayashi Y; Ando K
    Br J Haematol; 2014 Dec; 167(5):586. PubMed ID: 25256906
    [No Abstract]   [Full Text] [Related]  

  • 16. Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models.
    Dourado KMC; Baik J; Oliveira VKP; Beltrame M; Yamamoto A; Theuer CP; Figueiredo CAV; Verneris MR; Perlingeiro RCR
    Blood; 2017 May; 129(18):2526-2536. PubMed ID: 28351936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib.
    Chevalier N; Solari ML; Becker H; Pantic M; Gärtner F; Maul-Pavicic A; Hübner J; Wäsch R; Schmitt-Gräff A; Lübbert M
    Leukemia; 2010 Oct; 24(10):1779-81. PubMed ID: 20811401
    [No Abstract]   [Full Text] [Related]  

  • 18. Low platelet count reduces subsequent complete remission rate despite marrow with <5% blasts after AML induction therapy.
    Chen X; Newell LF; Xie H; Walter RB; Pagel JM; Sandhu VK; Becker PS; Hendrie PC; Abkowitz JL; Appelbaum FR; Estey EH
    Leukemia; 2015 Aug; 29(8):1779-80. PubMed ID: 25650090
    [No Abstract]   [Full Text] [Related]  

  • 19. Expression of pSTAT5 predicts FLT3 internal tandem duplications in acute myeloid leukemia.
    Obermann EC; Arber C; Jotterand M; Tichelli A; Hirschmann P; Tzankov A
    Ann Hematol; 2010 Jul; 89(7):663-9. PubMed ID: 20066533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneous sensitivity of human acute myeloid leukemia to β-catenin down-modulation.
    Gandillet A; Park S; Lassailly F; Griessinger E; Vargaftig J; Filby A; Lister TA; Bonnet D
    Leukemia; 2011 May; 25(5):770-780. PubMed ID: 21339756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.